文献速递肿瘤 PET/CT核素与放射性配体治疗

胰腺NET复发中的罕见胃转移:双示踪剂PET/CT与诊疗一体化

Unusual Gastric Metastases in the Setting of Recurrence of Pancreatic NET: Dual Tracer PET/CT and Theranostic Approach.
PubMed 文献 · Clin Nucl Med · 2026-10-23

本文报道一例胰腺神经内分泌肿瘤(NET)术后长期无进展后复发的病例,[68Ga]Ga-DOTATATE-PET/CT发现胃壁转移灶;[18F]F-FDG-PET/CT显示病灶对FDG亲和,提示需单纯化疗或联合[177Lu]Lu-DOTATATE肽受体放射性核素治疗(PRRT)。双示踪剂PET/CT在识别少见转移部位及制定治疗策略中起重要作用。

要点

  • 胰腺NET术后长期随访中,DOTATATE-PET/CT可识别胃壁等少见复发转移部位。
  • FDG-PET/CT显示的FDG亲和性可提示化疗或联合PRRT的治疗需求。
  • 双示踪剂PET/CT有助GEP-NET复发后的治疗策略选择。

核心结论

  • 胰腺NET术后长期无进展后复发,双示踪剂PET/CT可识别胃壁罕见转移并指导治疗选择。

研究设计与样本

  • 个案报道:一例胰腺NET术后患者,行[68Ga]Ga-DOTATATE-PET/CT与[18F]F-FDG-PET/CT双示踪剂显像。

主要发现

  • [68Ga]Ga-DOTATATE-PET/CT在长期无进展期后识别出胃壁转移为疾病复发。
  • 病灶在[18F]F-FDG-PET/CT上呈FDG亲和,提示需单纯化疗或联合[177Lu]Lu-DOTATATE PRRT。

临床怎么用

  • 对胰腺NET术后长期随访患者,复发评估可考虑双示踪剂PET/CT以发现少见转移部位。
  • 依据DOTATATE与FDG显像结果,协助判断化疗或联合PRRT的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gastric metastases from neuroendocrine tumors (NET) are infrequently encountered. Commonly, locally advanced pancreatic NET can involve stomach resulting in inoperable presentation. We herein present a case of gastric wall metastatic disease in postoperative pancreatic NET, which was identified on [68Ga]Ga-DOTATATE-PET/CT as recurrence of disease after prolong progression-free period. [18F]F-FDG avidity of the lesions on [18F]F-FDG-PET/CT indicated requirement of chemotherapy alone, or in combination with [177Lu]Lu-DOTATATE peptide receptor radionuclide therapy (PRRT). Hence, dual-tracer PET/CT imaging proved important in identifying unusual metastatic disease site and deciding therapeutic strategies in GEP-NET after a long follow-up period following surgical removal of primary disease.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Bagasariya R, Parghane RV, Basu S, et al. Unusual Gastric Metastases in the Setting of Recurrence of Pancreatic NET: Dual Tracer PET/CT and Theranostic Approach. Clin Nucl Med. 2026. PMID: 42912550. doi:10.1097/RLU.0000000000006481

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。